Stockscreener 앱 받기
3.65
4.29%
0.15
전일 마감가:
$3.50
열려 있는:
$3.47
하루 거래량:
2.30M
Relative Volume:
0.99
시가총액:
$243.21M
수익:
$80.00M
순이익/손실:
$-76.12M
주가수익비율:
-3.1836
EPS:
-1.1465
순현금흐름:
$-63.88M
1주 성능:
+4.29%
1개월 성능:
+4.29%
6개월 성능:
-64.00%
1년 성능:
-54.03%
1일 변동 폭
$3.46
$3.785
1주일 범위
$3.41
$3.785
52주 변동 폭
$2.83
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
3.65 | 233.22M | 80.00M | -76.12M | -63.88M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-12 | 개시 | JP Morgan | Overweight |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-07-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2023-09-25 | 개시 | Goldman | Neutral |
| 2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
BlackRock Portfolio Management LLC discloses 6.0% holding in THERAPEUTICS INC (FULC) - Stock Titan
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
Form 4 Fulcrum Therapeutics Inc For: 15 July By Investing.com - Investing.com South Africa
Kaplan Fox & Kilsheimer LLP Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to a Securities Investigation - NewMediaWire
Kevin Tang buys $891k of Fulcrum Therapeutics stock - Investing.com
Fulcrum Therapeutics, Inc. (FULC) gains Tang Capital as 10.4% shareholder - Stock Titan
Fulcrum Therapeutics (FULC) holder adds 249,946 shares in open-market buys - Stock Titan
Fulcrum Therapeutics (FULC) insider reports 6,663,383-share Tang Capital stake - Stock Titan
Frontier tech research, news & data - MLQ.ai
Fulcrum Therapeutics (FULC) loses 51% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Fulcrum Therapeutics (FULC) Slides 3.7% as Sellers Test Key Support Near $3.45Charm Flow - dars.gov.et
Fulcrum Therapeutics Inc. (FULC) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Market ReactionRevenue Surprise History - dars.gov.et
Fulcrum Therapeutics (FULC) director awarded 32,000 options at $3.66 - Stock Titan
Fulcrum Therapeutics (FULC) director awarded 32,000 stock options - Stock Titan
Fulcrum Therapeutics (FULC) director receives 32,000 stock options at $3.66 strike - Stock Titan
Fulcrum Therapeutics (FULC) director granted 32,000 stock options at $3.66 strike - Stock Titan
[Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity - Stock Titan
Fulcrum Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director King Rachel K. - Moomoo
After plunging 21.5% in 4 weeks, here's why the trend might reverse for Fulcrum Therapeutics (FULC) - MSN
Fulcrum Therapeutics | 8-K: Current report - Moomoo
Insider Sell Alert: Alan Ezekowitz Sells 18,000 Shares of Fulcru - GuruFocus
Fulcrum Therapeutics (FULC) director sells 18,000 shares under 10b5-1 plan - Stock Titan
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 3000E Growth Benchmark - marketscreener.com
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End - Eastern Progress
Price to sales forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to book forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Price to earnings forward of Fulcrum Therapeutics, Inc. – NASDAQ:FULC - TradingView
Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit - Yahoo Finance
Fulcrum Therapeutics (FULC) Surges 5.26% as Biotech Momentum Builds, Testing Key ResistanceHigh Dividend Factor - dars.gov.et
[144] Fulcrum Therapeutics, Inc. SEC Filing - Stock Titan
Fulcrum Therapeutics, Inc. Actuals & Estimates (NASDAQ:FULC) - TradingView
EcoR1, Oleg Nodelman disclose 9.0% stake in Fulcrum (NASDAQ: FULC) - Stock Titan
EcoR1 Capital (FULC) reports shared control of 6.0M shares; 9.0% stake - Stock Titan
Fulcrum Therapeutics Shareholders Reaffirm Board and Governance Structure - TipRanks
Fulcrum Therapeutics (FULC) details 2026 stockholder voting on directors and key proposals - Stock Titan
Fulcrum Therapeutics Inc (FULC) Institutional Confidence - TradingKey
Fulcrum Therapeutics (FULC) Advances 1.8% as Shares Test Resistance Near $4.12Growth ETF - dars.gov.et
Fulcrum Therapeutics Inc (FULC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fulcrum plunges after discontinuing lead program - MSN
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securiti - The National Law Review
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-06-19 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out | NDAQ:FULC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations - NewMediaWire
Fulcrum Therapeutics Inc (FULC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.80%
2.11%
자본화:
|
볼륨(24시간):